On Jun 18, 2014, we issued an updated research report on
Abaxis tumbled once again in the fourth quarter of fiscal 2014
with earnings per share of 17 cents missing the Zacks Consensus
Estimate by 3 cents. Earnings also slid from the year-ago number by
a massive 43.3%. Revenues also fell 15.8% to $42.0 million lagging
the Zacks Consensus Estimate of $46 million.
The company delivered a disappointing performance in mainstay
North America although revenues from international markets
improved. The Veterinary Market segment performed feebly while
Medical Market showed an improvement.
Despite that, positive investor reaction led to a sharp 5.2%
increase in the company's stock price following the earnings
release. We believe the upside was primarily driven by two
Firstly, investor optimism with regard to management's
conviction that the company is likely to achieve double-digit
growth in fiscal 2015 may have boosted the share price. Despite the
presence of several near-term challenges, the company has set goals
to return to double-digit growth on both top and bottom-line fronts
in 2015. With a full year of partnership with Abbott now complete,
the domestic Medical Market segment looks forward to resume
double-digit growth in fiscal 2015.
Additionally, Abaxis Veterinary Reference Laboratories (AVRL)
continues to be a priority, increasing sales growth and reducing
loss by targeting customers who are mostly likely to benefit from
the approach of splitting the sample and running the routines
in-house on point-of-care equipment and from using AVRL for their
specialty test needs.
Secondly, the initiation of quarterly dividend of 10 cents per
share on the back of strong cash flow and expected healthy
financial performance also may have led to the upside.
Abaxis has delivered negative surprises in each of the last four
quarters, with an average miss of 25.12%. The stock currently
carries a Zacks Rank #3 (Hold).
Other Stocks to Consider
Investors interested in the broader medical sector can consider
Natus Medical Inc.
). All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ACCURAY INC (ARAY): Free Stock Analysis Report
ABAXIS INC (ABAX): Free Stock Analysis Report
MASIMO CORP (MASI): Free Stock Analysis Report
NATUS MEDICAL (BABY): Free Stock Analysis
To read this article on Zacks.com click here.